RT Journal Article
SR Electronic
T1 High Incidence of GalNAc Disialosyl Lactotetraosylceramide in Metastatic Renal Cell Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4345
OP 4350
VO 27
IS 6C
A1 RYO MARUYAMA
A1 SEIICHI SAITO
A1 VLADIMIR BILIM
A1 NOBORU HARA
A1 TOSHIYUKI ITOI
A1 KAZUTOSHI YAMANA
A1 TSUTOMU NISHIYAMA
A1 YOICHI ARAI
A1 KOTA TAKAHASHI
A1 YOSHIHIKO TOMITA
YR 2007
UL http://ar.iiarjournals.org/content/27/6C/4345.abstract
AB Background: In renal cell carcinoma (RCC), glycosphingolipids monosialosyl globopentaosylceramide (MSGb5) and GalNAc disialosyl lactotetraosylceramide (GalNAcDSLc4) were shown to be predictors of metastasis. Here we extended the research using a larger cohort of patients with a longer follow-up period, and reevaluate their relationship to malignant potential, metastasis and prognosis in patients with RCC. Patients and Methods: MSGb5 and GalNAcDSLc4 were examined in 114 primary RCCs by immunohistochemical method on cryostat sections. Results: GalNAcDSLc4 was detected in 13.2% of RCCs and was associated with a significantly higher incidence of metastasis at the time of primary visit (60.0% vs. 31.3%, p=0.0419) as well as de novo metastasis during follow-up (33.3% vs. 14.7%), and a shorter survival (p=0.0399). MSGb5 was detected in 51.8% of tumors and was not related to clinocopathological characteristics or survival. Conclusion: RCC patients with tumors positive for GalNAcDSLc4 are at higher risk of metastasis at the time of diagnosis and during follow-up. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved